LC
MRSN

Lindbrook Capital’s Mersana Therapeutics MRSN Stock Holding History

Lindbrook Capital’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18
Closed -$2.61K – 2862
2022
Q4 		$2.61K Hold
18
– – ﹤0.01% 2117
2022
Q3 		$3K Buy
+18
New +$2.92K ﹤0.01% 1893
2022
Q2 		– Sell
-26
Closed -$2.44K – 2662
2022
Q1 		$3K Buy
+26
New +$3.04K ﹤0.01% 1846
2020
Q3 		– Sell
-20
Closed -$12K – 1812
2020
Q2 		$12K Buy
+20
New +$6.83K ﹤0.01% 780
2020
Q1 		– Sell
-80
Closed -$14K – 1792
2019
Q4 		$11K Buy
+80
New +$5.85K ﹤0.01% 905

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Lindbrook Capital's MRSN Position: Q1 2023 in Review

Lindbrook Capital sold out of Mersana Therapeutics (MRSN) in Q1 2023, closing a stake of 18 shares — an estimated $2.61K sold.

Lindbrook Capital first reported a position in MRSN in Q4 2019 and held it in 5 quarters. The position peaked at $12K in Q2 2020. 157 funds tracked by Wall St. Rank hold MRSN as of Q1 2023.

  • Lindbrook Capital reported no remaining Mersana Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Lindbrook Capital sold 18 Mersana Therapeutics shares in Q1 2023, an estimated $2.61K.
  • Lindbrook Capital first reported a position in Mersana Therapeutics in Q4 2019 and held it in 5 quarters.
  • Lindbrook Capital's Mersana Therapeutics position peaked at $12K in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2023.

Based on Lindbrook Capital's 13F filing for Q1 2023, filed 26 Apr 2023.